Discovery and Synthesis of HIV Integrase Inhibitors: Development of Potent and Orally Bioavailable N-Methyl Pyrimidones
- 8 September 2007
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (20) , 4953-4975
Abstract
The human immunodeficiency virus type-1 (HIV-1) encodes three enzymes essential for viral replication: a reverse transcriptase, a protease, and an integrase. The latter is responsible for the integration of the viral genome into the human genome and, therefore, represents an attractive target for chemotherapeutic intervention against AIDS. A drug based on this mechanism has not yet been approved. Benzyl-dihydroxypyrimidine-carboxamides were discovered in our laboratories as a novel and metabolically stable class of agents that exhibits potent inhibition of the HIV integrase strand transfer step. Further efforts led to very potent compounds based on the structurally related N−Me pyrimidone scaffold. One of the more interesting compounds in this series is the 2-N-Me-morpholino derivative 27a, which shows a CIC95 of 65 nM in the cell in the presence of serum. The compound has favorable pharmacokinetic properties in three preclinical species and shows no liabilities in several counterscreening assays.Keywords
This publication has 32 references indexed in Scilit:
- Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase InhibitorsJournal of Medicinal Chemistry, 2007
- From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moietyBioorganic & Medicinal Chemistry Letters, 2007
- 4,5-Dihydroxypyrimidine Carboxamides and N-Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical SpeciesJournal of Medicinal Chemistry, 2006
- Inhibitors of HIV-1 protease: 10 years afterExpert Opinion on Therapeutic Patents, 2006
- Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitorsExpert Opinion on Therapeutic Patents, 2006
- 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of the Hepatitis C Virus NS5B Polymerase: Discovery, SAR, Modeling, and MutagenesisJournal of Medicinal Chemistry, 2006
- Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acidBioorganic & Medicinal Chemistry Letters, 2004
- A convenient synthesis of 6-acetyl-1,2,3,4-tetrahydropyridine, the principle bread flavor componentThe Journal of Organic Chemistry, 1993
- Syntheses of proline analogs as potential mechanism-based inhibitors of proline dehydrogenase: 4-methylene-L-, (E)- and (Z)-4-(fluoromethylene)-L-, cis- and trans-5-ethynyl-(.+-.)-, and cis- and trans-5-vinyl-L-prolineThe Journal of Organic Chemistry, 1992
- Synthesis of 5,6‐dihydroxy‐2‐phenyl‐4‐pyrimidinecarboxylic acid, methyl ester, a corrected structureJournal of Heterocyclic Chemistry, 1979